W1P3 Flashcards
(151 cards)
Viruses
- type
- replication process
Viruses are obligate intracellular parasites
Viral replication depends primarily on synthetic processes of the host cell
Antiviral agents must ideally inhibit virus-specific events:
Block viral entry into the cell
Block viral exit from the cell
Be active inside the host cell
Exert some sort of immunomodulatory effect
What are the viral events that antivirals need to target
Antiviral agents must ideally inhibit virus-specific events:
Block viral entry into the cell
Block viral exit from the cell
Be active inside the host cell
Exert some sort of immunomodulatory effect
How is an antiviral’s therapeutic effect measured?
Since viruses are not “alive”, drugs cannot “kill” them
A therapeutic agent’s antiviral effect is measured by its ability to inhibit viral replication:
- 50% Inhibitory Concentration (IC50). should have half as many virally infected cells compared to when we started after giving antiviral
Steps of Viral Replication
- Attachment
- Entry
- Uncoating
- Synthesis
a. Early proteins
b. Nucleic acids
c. Late proteins - Assembly
- Release
Who are the people in Canada who are at high risk of influenza- related complications and thus should be vaccinated
Adults aged > 65 years; residents of nursing homes or long-term care facilities
All children aged <5 years, especially 6 to 23 months
children above 6 months should get vaccinated
Canada approved antivirals for Influenza
Oseltamivir (PO)
Zanamivir (inhalation)
Peramivir (IV) [Not marketed in Canada]
Baloxavir Marboxil (PO)
Oseltamivir (PO)
Oral capsule, liquid suspension
Aged >14 d
Generic version available
Antivirals for Influenza
Zanamivir (inhalation)
Powder for oral inhalation through a plastic device
Aged ≥7 y
Not recommended in patients with airway diseases (eg asthma, COPD)
Antivirals for Influenza
Peramivir (IV)
Given intravenously
Aged ≥2 y
appoved for use but Not marketed in Canada
Antivirals for Influenza
Baloxavir Marboxil (PO)
Oral tablets (1 dose) Aged ≥12 y (FDA approval pending for patients aged 1-11 y) - for non severe cases
Antivirals for Influenza
What are all circulaing influenze viruses RESISTANT to?
Adamantanes
Adamantanes
M2 ion inhibitors for influenza virus that has become useless because of resistance
Point mutation of the M2 protein lead to resistance
Resistance emerges rapidly during treatment
- 30% of adults and 80% of children treated with amantadine will excrete resistant virus
- Persistant or recurrent fever in children who develop amantadine-resistant strains on treatment
Viral replication, transmission and virulence are not impaired by these mutations
Neuraminidase Inhibitor
Neuroaminidase is a receptor/ active site*
NA^ inhibitors: Cleave the bond between HA (on virus) and sialic acid receptor on host epithelial cells which is otherwise used to attach the virus to host
Neuraminidase inhibitor = cleaves the bond stated above ^ = clumping of viral particles = shutting down replication
Resistance to oseltamivir does not necessarily confer resistance to zanamivir
Mutations in the receptor affect the conformational change of the oseltamivir = antibiotic resistance
But this doesn’t affect zanamivir: mutations that prevent this conformational change prevent binding of oseltamivir (Panel B). Zanamivir and sialic acid still bind to NA active site despite H274Y mutation
Polymerase Inhibitors: Mechanism of Action1
polymerase inhibitors: inhibit ENDONUCLEASE activity
Benefits of Oseltamivir therapy
REDUCTION of
- Duration of illness in adults and children
0. 5 to1.5 days or 25-32% - Viral shedding and viral load
- need for Antibiotics
- length of hospializations
- hospital mortality
- however you need to be treated EARLY. It peaks at day 2*
Who do you treat with Oseltamivir
- During periods of community circulation of influenza viruses
Prompt empiric treatment is recommended for persons with suspected or confirmed influenza and:
- Respiratory illness requiring hospitalization
- Outpatients with progressive, severe, or complicated illness
- Outpatients at higher risk for influenza complications (i.e. pneumonia)
- Outpatients without risk factors but presenting early (<48 h) on a case-by-case basis
Prophylaxis of influenza contacts?
Prophylaxis (HALF THE DOSE of oseltamivir/zanamivir) of household contacts
- Reduces transmission
- Previously recommended for high-risk contacts
Early treatment of contacts may now be preferred
- NOT GOOD if they are already infected, because then if you give them half dose; you’re exposing the virus to subtherapeutic environment which PROMOTES resistance
Take home points for Infuenza
- treatment
- Window to treat?
- Resistance characteristic in influenza?
Antivirals are beneficial in treatment of influenza
Early treatment (<48 hrs) increases benefits - Severe disease, immunocompromised may still benefit from late treatment (up to 5 days)
Influenza has the ability to change rapidly
Next year’s circulating strains and their resistance profiles will determine best treatment strategies
Physicians need to stay up to date
http://www.phac-aspc.gc.ca/fluwatch/index-eng.php
Herpes Simplex Virus
These are enveloped, double stranded DNA viruses
Uses the Lytic cycle to transcribe viral DNA by the host cell and form new viral proteins
They can also travel up sensory neurons to start the LATENT cycle
stay FOR LIFE.
Commonly asymptomatic.
Symptoms include skin and mucous membrane lesions:
HSV1: Infections above the waist (mouth and tongue)
HSV2: infection below the waist (genitals)
* however there is a lot of cross over.
Herpes lesions in the mouth look like….
Cluster of small, painful, fluid-filled blisters
- They ooze and ulcerate
- Heal in a few weeks
Herpes has dormant stages and reactivation stages, it comes and goes.
reactivation is often asymptomatic BUT when it is,
you’ll see handful of blisters at the vermillion border (lip) on ONE side of the face
- these blisters a small and typically heal in a week
Acyclovir active against…
Active against:
HSV
VZV, varicella (lower affinity, thus requires higher doses)
Very poor activity against other herpesviruses
15-30% bioavailability p.o. (poor, need IV)
Acyclovir mechanism of action
Triphosphate form inhibits viral DNA synthesis by:
1) competing with dGTP for viral DNA polymerase
2) chain termination
Acyclovir - Resistance
in HSV and VZV
HSV Most often due to virus DEFICIENCY in TK [thymidine kinase, the target for this drug] Rarely due to altered TK or DNA pol Rare in immunocompetent 4-17% of isolates in immunocompromised
VZV
Mostly ALTERED TK (lower affinity for ACV)